Stock 300705 HUNAN JIUDIAN PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Hunan Jiudian Pharmaceutical Co., Ltd.

Equities

300705

CNE1000034Z6

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-28 pm EDT 		5-day change 1st Jan Change
36.81 CNY +1.63% Intraday chart for Hunan Jiudian Pharmaceutical Co., Ltd. +2.00% +10.77%
Apr. 25 Hunan Jiudian Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023 CI
Apr. 24 Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Strengths

  • Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
  • The company's profit outlook over the next few years is a strong asset.
  • The group's high margin levels account for strong profits.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.

Weaknesses

  • With a 2024 P/E ratio at 25.04 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
  • The company appears highly valued given the size of its balance sheet.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
HUNAN JIUDIAN PHARMACEUTICAL CO., LTD. Stock Hunan Jiudian Pharmaceutical Co., Ltd.
+10.77% 1.73B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.47% 661B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.74% 566B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 352B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.35% 332B
B-
ABBVIE INC. Stock AbbVie Inc.
+4.23% 283B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.43% 231B
B+
NOVARTIS AG Stock Novartis AG
+4.71% 200B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-9.53% 195B
A+
AMGEN INC. Stock Amgen Inc.
-4.04% 145B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
-
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 300705 Stock
  4. Ratings Hunan Jiudian Pharmaceutical Co., Ltd.